Basestone Pharmaceuticals: The new indication for the third stage of Deqilinumab in non-small cell lung cancer has been approved by the UK MHRA.

On February 23, JiShi Pharmaceutical announced that the new indication application for the drug pembrolizumab has been approved by the UK MHRA for use in treating unresectable stage III NSCLC adult patients who have not shown disease progression after platinum-based chemotherapy, with tumor cell PD-L1 expression 1%, without EGFR sensitive mutations or ALK, ROS1 gene alterations.